G - CH2 Acquired pneumonias in the community

Maresme Area Research Group for acquired pneumonias in the community

The GEMPAC (Maresme Research Group for Community Acquired Pneumonia) is a consolidated group recognized by the Agency for University Grants of the Generalitat of Catalunya (AGAUR). It is physically located at the Maresme Health Consortium, which covers primary health care in the Maresme region and is centred in the Mataró Hospital and has a collaborative agreeement with the IGTP for research activities.  The group has been led by Dr Jordi Almirall for more than 25 years and carries out epidemiological studies for lower tract respiratory infections; these studies are coordinated by the Mataró Hospital.   The group has made important contributions in the areas of incidence, microbiology, prognostic risk factors, costing, diagnostic errors and the value of inflammatory markers for the prediction of pneumonia and aetiological orientation. 

The group has be awarded eight FIS grants in which different specialists have participated as principal investigator including family doctors, hospital specialists and house doctors, both from Mataró and other hospitals, nursing staff have also taken part.  Since 2006 the group has formed part of the CIBERES network within the Group 14 led by Dr Antoni Torres from the Clinic Hospital Barcelona and Barcelona University for research into aetiology, prognostic risk factors associated with community acquired lower tract respiratory infections (LRTI).

GEMPAC researchers have also participated in as partners in European projects such as GRACE (Genomics to combat Resistance against Antibiotics in Community acquired LRTI in Europe) of the Sixth framework programme priority.  Since 2012 they have participated in the European Network COMBACTE CLIN-Net and LAB net (Innovative Initiatives in Medicine) to carry out clinical trials with new antibiotics with the coordinators Dr. H. Goossens (Antwerp) i Dr. Harbarth (Geneva).  They are also currently part of the PREPARE project (Work Packages 3 and 5) (www.prepare-europe.eu/).

The group also has eight contracts with pharmaceutical companies to carry out clinical trials.   The group has generated seven doctoral theses in recent years with another three currently in progress and has 40 international publications and 30 more in Spanish journals with a total impact factor of 204.

Research lines

  • Population study on acute COPD

Community study of diagnostic error for COPD, study of incidence of exacerbation of COPD, case-controlled study of risk factors for acute-prone phenotypes with the importance of oral hygiene, disphagia, diet (antioxidantes and vitamin D levels).

  • Study of risk factors for pneumonia in respiratory patients (asthma and COPD)

Community study of risk factors for pneumonia in asthmatic patients with COPD and the importance of the use of broncodilatotors and oral hygiene.  Study of the impact of biological markers and immunoglobulins in prognosis of communty acquired pneumonia

  • Study of infectious comorbidity in patients admitted to hospital for acute COPD

Study of the prevalence of infections in patients admitted to hospital for acute COPD for Clostridium difficille microbacteria infections and the impact of flu epidemic

  • Study of risk factors for community acquired pneumonia

Study of risk factors for community acquired pneumonia such as treatment with Benzodiazepine, dysphagia ,oral hygiene, occupation etc

More information

Contact

Jordi Almirall

(+34) 93 7417747

jalmirall(ELIMINAR)@csdm.cat